OMERS ADMINISTRATION Corp Purchases 12,656 Shares of Amgen Inc. $AMGN

OMERS ADMINISTRATION Corp increased its position in Amgen Inc. (NASDAQ:AMGN) by 60.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 33,633 shares of the medical research company’s stock after acquiring an additional 12,656 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Amgen were worth $11,008,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. High Note Wealth LLC boosted its position in shares of Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. lifted its position in Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after purchasing an additional 28 shares during the last quarter. Verus Capital Partners LLC lifted its position in Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 28 shares during the last quarter. Destination Wealth Management lifted its position in Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after purchasing an additional 29 shares during the last quarter. Finally, West Family Investments Inc. lifted its position in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Down 1.3%

AMGN stock opened at $350.53 on Tuesday. The company has a market capitalization of $189.18 billion, a PE ratio of 24.39, a price-to-earnings-growth ratio of 3.56 and a beta of 0.42. The company’s 50 day moving average price is $341.03 and its two-hundred day moving average price is $345.86. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts predict that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Guggenheim dropped their target price on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday, May 4th. Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Barclays assumed coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Finally, Leerink Partners reiterated a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $354.12.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.